Gamma hydroxybutyrate is associated with a disproportionate burden of harm despite low overall population prevalence of use.

Patients prescribed high doses of opioids need to be managed appropriately to reduce risks of morbidity and mortality.

Buprenorphine–naloxone is well tolerated by patients with chronic pain, and has the potential to improve pain scores and affective symptoms.